AP Biosciences (6945) Stock Overview

AP Biosciences, Inc. researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase II clinical trials for Senile macular degeneration patients; AP505 that is in phase I for solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, squamous cell head and neck cancer, squamous cell esophageal cancer, and other solid tumors; AP402 for breast cancer patients; and AP601 for lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.